RELATED ARTICLES
Disrupting Alzheimer's Disease
Researchers, patient advocates and policymakers recently gathered in Chicago to discuss the unique challenges that make up Alzheimer's research and what the future holds for the 5.7 million Americans living with the disease.
POPULAR ARTICLES
HIV/AIDS: From An Acute Fatal Disease to A Chronic, Manageable Condition
<p>The evolution of HIV/AIDS treatment is nothing short of remarkable. In the 1980s, HIV/AIDS was an acute fatal disease. Today it is a chronic, manageable condition thanks to the commitment of biopharmaceutical researchers, health care workers and advocates.</p>
READ MORE
Combatting Sickle Cell Disease with Cell & Gene Therapy
<p><span><span><span><a><span lang="EN"><span>America's biopharmaceutical companies are researching and developing new treatments to alleviate the tremendous burden of this devastating and painful disease and to improve the quality of life for sickle cell patients.</span></span></a></span></span></span></p>
READ MORE
Why Has Research into Alzheimer's Disease Been So Hard?
<p>Why, when we have seen such progress in our ability to treat other diseases, such as cancer, diabetes and HIV, has progress in Alzheimer's research been so difficult to achieve?</p>
READ MORE
5 Recent Developments Advancing Vaccines
As communities continue to grapple with the impact of COVID-19, vaccines have once again come to the forefront as a critical health care tool.
READ MORE
The Innovation Ecosystem Fuels Breakthroughs
Biopharmaceutical research companies are uniquely positioned to take the necessary risks to further advance research into safe and effective treatments for patients.
READ MORE
Understanding mRNA Vaccines
Scientists at Pfizer are breaking barriers with mRNA technology, one of the approaches used to develop COVID-19 vaccines.
READ MORE
Protecting Alzheimer's Research
15 million people will live with Alzheimer's by 2060. We're working to change that.
READ MORE